Phase 2 Sleep Disorders Trial, Recruiting NCT06981195 Sponsor: Virginia Commonwealth University Condition: Sleep Disorders
Back to Sleep Disorders

Phase 2 Sleep Disorders Trial, Recruiting

NCT06981195
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with opioid use disorder (OUD) of at least moderate severity, based on current diagnostic guidelines
  • You are currently receiving outpatient treatment for OUD using buprenorphine, either as a dissolvable film or tablet (between 8mg and 24mg) or as a monthly injectable form
  • You have been on your current buprenorphine dose for at least 4 weeks and there are no plans to change your dose in the next 3 months
  • A urine test at screening shows buprenorphine is present at appropriate levels, as confirmed by a study doctor
  • A urine test at screening shows no other non-prescribed substances (marijuana/cannabis is allowed), and a breath or saliva alcohol test is negative
  • You screen positive for long-term sleep problems (chronic insomnia) based on a specific sleep questionnaire used in the study
  • Your insomnia symptom score is 13 or higher on a standard rating scale, both at screening and at the start of the study
  • You do not have any significant medical or mental health conditions that a study doctor believes would make participation unsafe
  • You can understand the study procedures and are able to sign a consent form written in English
  • You have access to a computer or smartphone with internet or cell service to complete online surveys and monitoring

Who may not be able to join:

  • You have been diagnosed with a sleep-related breathing disorder, narcolepsy, sleepwalking, or sleep paralysis
  • You screen positive for sleep apnea based on a questionnaire or a home sleep test showing certain levels of breathing interruptions or drops in blood oxygen during sleep (confirm with trial site)
  • You are currently receiving any treatment for insomnia, whether that is therapy (such as talk therapy for sleep) or medication
  • You are currently taking any prescribed or over-the-counter medication or supplement to help with sleep (such as zolpidem/Ambien), or you are unable to stop taking such a product
  • You are currently taking benzodiazepines (such as Valium or Xanax), other opioids besides buprenorphine, antipsychotics, or other medications that affect the brain and nervous system that could increase safety risks
  • You have a current diagnosis of alcohol or drug use disorder (other than nicotine) and have used non-prescribed substances in the past 3 months
  • You use cannabis/marijuana more than 3 days per week
  • You have an uncontrolled serious mental health condition such as Bipolar I Disorder, ADHD, Schizophrenia, schizoaffective disorder, major depression with psychotic features, or a neurological disorder
  • You have an uncontrolled serious condition affecting the nervous system, heart, or lungs, such as a seizure disorder, recent heart attack, stroke, or a recent hospital stay for a lung condition
  • Your heart test (ECG) at the start of the study shows a significant abnormality, including a specific heart rhythm measurement (QTc) above 450ms
  • You currently have significant thoughts of harming yourself or others, or you have attempted suicide in the past 6 months
  • Your blood test results show that your liver or kidney function values are significantly above the normal range (confirm with trial site for specific numbers)
  • You are pregnant, breastfeeding, or — if there is a possibility you could become pregnant — you are unwilling to use an acceptable form of birth control during the study
  • You are currently taking certain prescription or over-the-counter medications or supplements that are known to strongly interact with how the body processes some drugs — this includes certain antibiotics, antifungals, HIV medications, and herbal supplements such as St. John's Wort (confirm with trial site for the full list)
  • You are currently taking a sleep medication called lemborexant, or you have had a bad reaction to lemborexant or similar medications in the past
  • You are currently incarcerated or facing upcoming incarceration

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Caitlin E Martin, MD, Virginia Commonwealth University Institute for Drug and Alcohol Studies

Phone: 804-827-3784

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
27 May 2025
Est. completion
30 July 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Insomnia; Impulsivity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov